US Bio CEO Realizes Stock Option Gains Worth 20 Billion Won

United Therapeutics Corp (NASDAQ: UTHR) CEO Martin Rothblatt exercised 9,500 stock options on April 10 and sold them the same day, raising about $5.4 million (roughly ₩7 billion). He followed up on April 14 and 15 by exercising and selling approximately 19,000 additional options, realizing another $11 million (about ₩15 billion), the company disclosed. The filing also retroactively corrected a small sale of common shares executed on March 13 through a family trust. Rothblatt still holds roughly 40,000 common shares and retains a significant economic interest in the company via his family trust stake.

Chief Financial Officer James Edgemon exercised about 10,000 options on April 13, sold the majority of them to generate $5.7–5.8 million (around ₩8 billion), and continues to own about 18,000 common shares.

On May 11, at the American Thoracic Society Conference (ATS 2026), United Therapeutics presented new data from its key clinical trials—TETON-1 and ADVANCE OUTCOMES—targeting pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). In its Q1 2026 results released May 6, the company reported revenue of $781.5 million (approximately ₩1.05 trillion), a 2% decline year-over-year, and earnings per share of $5.82, falling short of market expectations.

Founded in 1996, United Therapeutics is a U.S. biotech firm developing therapies for rare cardiopulmonary diseases such as PAH, alongside artificial and xenogeneic organ transplantation technologies. The company is best known for its Tyvaso franchise, which is based on treprostinil. Rothblatt, an entrepreneur who established United Therapeutics to find a treatment for his daughter’s life-threatening rare disease, leads its organ manufacturing and xenotransplantation research. In 2026, he was elected to the U.S. National Academy of Engineering and is widely recognized as an innovation leader in the bio- and engineering fields.